Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma

NCT05066802 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05066802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
May 11, 2020
Completion date
May 31, 2023
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic adenocarcinoma